--- title: "16:48 ETQURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit" description: "Rosen Law Firm has announced a class action lawsuit for investors who purchased shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025. Investors may be entitled to com" type: "news" locale: "en" url: "https://longbridge.com/en/news/277252635.md" published_at: "2026-02-27T21:48:55.000Z" --- # 16:48 ETQURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit > Rosen Law Firm has announced a class action lawsuit for investors who purchased shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025. Investors may be entitled to compensation without upfront fees. The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application. Interested investors can join the class action by contacting the firm before April 13, 2026. , /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. So What: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case\_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food and Drug Administration (the "FDA"); (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application ("BLA") timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants' statements about uniQure's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case\_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 \[email protected\] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. ### Related Stocks - [QURE.US - Uniqure](https://longbridge.com/en/quote/QURE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | uniQure N.V.的投资者有机会主导证券欺诈诉讼 | 罗森律师事务所宣布对在 2025 年 9 月 24 日至 2025 年 10 月 31 日期间购买 uniQure N.V.（纳斯达克代码：QURE）股票的投资者提起集体诉讼。投资者可能有权在没有前期费用的情况下获得赔偿。诉讼声称 uniQ | [Link](https://longbridge.com/en/news/276567346.md) | | 美股盘中速递：uniQure 跌近 10%，成交量放大，市场波动性显著 | uniQure 跌 9.87%；阿里拉姆制药跌 6.23%，成交额达到 9.78 亿美元；Abivax SA 涨 4.72%，成交额达到 7.01 亿美元；再生元制药跌 2.98%，成交额达到 6.28 亿美元；艾伯维市值达到 3889 亿 | [Link](https://longbridge.com/en/news/272314286.md) | | Clarivate｜8-K：2025 财年 Q4 营收 6.17 亿美元超过预期 | | [Link](https://longbridge.com/en/news/276722157.md) | | 费森尤斯预计 2026 财年将实现有机收入增长 | 费森尤斯预测 2026 财年有机收入增长 | [Link](https://longbridge.com/en/news/276846704.md) | | 帝亚吉欧预计 2026 财年的有机运营利润增长将保持平稳或实现低个位数的增长 | 帝亚吉欧预计 2026 财年的有机营业利润增长将持平或低个位数增长 | [Link](https://longbridge.com/en/news/276851205.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.